AbCellera Biologics Inc. - Common Shares (ABCL)

AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause.

AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 (“the ‘408 Patent”). AbCellera’s ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.

AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California.

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30, 2025.

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

AbCellera (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois.

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas.

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas.

AbCellera (Nasdaq: ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:

AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera’s COVID-19 antibody program.

AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time).

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology.